acquisition
AstraZeneca to acquire Fusion for approximately $2bn
March 19, 2024Business Services AstraZeneca, Fusion Pharmaceuticals, Oncology, acquisition, radioconjugates
AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. This …
AstraZeneca to acquire Amolyt Pharma for up to $1.05bn
March 14, 2024Business Services Amolyt Pharma, AstraZeneca, Rare Diseases, acquisition, rare diseases
AstraZeneca has announced that it has entered into a definitive agreement under which it will acquire Amolyt Pharma for up …
Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn
March 11, 2024Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …
Aspire Pharma acquires Cenoté Pharma
March 11, 2024Business Services Aspire Pharma, Cenoté Pharma, Pharmacy, acquisition
Aspire Pharma has announced that it has successfully acquired Cenoté Pharma as part of its plan to supplement its growth …
Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma
February 7, 2024Business Services Pharmacy, RedX Pharma, acquisition, jazz pharmaceuticals
Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire …
Novartis to acquire MorphoSys AG for €2.7bn
February 6, 2024Business Services Novartis, Pharmacy, acquisition, morphosys
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
February 5, 2024Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
January 31, 2024Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …
Oxford Biomedica acquires ABL Europe for €15m
January 30, 2024Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …
Sanofi to acquire Inhibrx for approximately $1.7bn
January 23, 2024Business Services Inhibrx, Rare Diseases, Sanofi, acquisition
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
GSK to acquire Aiolos Bio for $1bn
January 9, 2024Business Services Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …
Calypso Biotech to be acquired by Novartis for $250m
January 8, 2024Business Services Calypso Biotech, Immunology, Novartis, acquisition
Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …
AstraZeneca to acquire Icosavax for up to $1.1bn
December 12, 2023Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines
AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …
AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn
December 7, 2023Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition
AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …
Latest content
Five Facts about cardiovascular disease
